米国のポイントオブケア薬物乱用検査市場規模、シェア、動向分析レポート：製品別、サンプルタイプ別、技術別、最終用途別、セグメント別予測、2025年～2033年

米国のポイントオブケア薬剤乱用検査市場概要

米国のポイントオブケア薬剤乱用検査市場規模は、2024年に3億7,055万米ドルと推定され、2025～2033年にかけてCAGR 9.3％で成長すると予測されます。この市場を牽引しているのは、複数の環境における迅速かつオンサイトの薬剤検査に対するニーズの高まりです。尿、唾液、時には血液ベースパネルを含むポイントオブケアDOA検査は、職場、救急部、警察、リハビリセンター、学校などで広く利用されています。これらの検査はすぐに結果が出るので、ヘルスケア専門家や医療機関が、患者ケア、コンプライアンス、リスク軽減に関連した意思決定を迅速に行うのに役立ちます。携帯性と使いやすさが検査室以外の専門家への普及をさらに促進し、市場浸透に寄与しています。

市場促進要因の一つは、米国における薬剤乱用、特にオピオイド、大麻、コカイン、アンフェタミンの蔓延です。全米薬剤乱用統計センターによると、2023年には12歳以上のアメリカ人のうち2,000万人以上が薬剤使用障害を抱えています。このような動向の高まりにより、特に救急医療や産業保健の現場において、効率的な薬剤スクリーニングツールの需要が高まっています。さらに、SAMHSA（薬剤乱用・精神衛生サービス局）などの連邦機関や州レベルのオピオイド対応プログラムからの資金援助が増加したことで、迅速な検査ツールの採用が後押しされています。

運輸、建設、ヘルスケアなど安全性が重視される産業では、雇用前、無作為、事故後の薬剤検査が義務付けられており、市場の成長に大きく寄与しています。米国運輸省（DOT）やその他の規制機関は、雇用主にDOAスクリーニングプロトコルの実施を強制する厳しい要件を定めています。POC検査は、酩酊状態や最近の薬剤使用を迅速に特定する能力により、これらの環境で特に評価されており、法的責任を軽減し、労働者の安全を確保するのに役立っています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のポイントオブケア薬剤乱用検査市場の変数、動向、範囲

• 市場のイントロダクション/系統展望
• 市場規模と成長展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
  • 市場課題分析
• 米国のポイントオブケア薬剤乱用検査市場分析ツール
  • ポーター分析
  • PESTEL分析

第4章 米国のポイントオブケア薬剤乱用検査市場：製品別、推定・動向分析

• 米国のポイントオブケア薬剤乱用検査市場：製品変動分析
• 製品別、2024年と2033年
• 免疫測定テストストリップとカセット
• 口腔液検査キット
• 呼気分析装置
• 尿収集カップ
• デジタル/ポータブル分析装置

第5章 米国のポイントオブケア薬剤乱用検査市場：サンプルタイプ別、推定・動向分析

• 米国のポイントオブケア薬剤乱用検査市場：サンプルタイプ変動分析
• サンプル別、2024年と2033年
• 尿
• 唾液（口腔液）
• 呼吸
• 血液
• 汗/髪

第6章 米国のポイントオブケア薬剤乱用検査市場：技術別、推定・動向分析

• 米国のポイントオブケア薬剤乱用検査市場：技術変動分析
• 技術別、2024年と2033年
• ラテラルフローアッセイ（LFA）
• クロマトグラフィー免疫測定
• 酵素免疫測定（ELISA）
• 質量分析（ポータブルまたはハイブリッドPOCユニット）

第7章 米国のポイントオブケア薬剤乱用検査市場：最終用途別、推定・動向分析

• 米国のポイントオブケア薬剤乱用検査市場：最終用途変動分析
• 最終用途別、2024年と2033年
• 病院と救急科
• 職場・労働衛生センター
• 在宅医療とリモートユーザー
• その他

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 企業ヒートマップ分析
• 企業プロファイル
• 企業プロファイル/上場企業
  • Abbott
  • Quest Diagnostics Inc
  • Thermo Fisher Scientific
  • OraSure Technologies
  • Siemens Healthineers
  • F. Hoffmann-La Roche Ltd.
  • Dragerwerk AG & Co. KGaA
  • Premier BIoTech
  • American Screening Corporation, Inc.
  • Aegis Sciences Corporation
  • MP Biomedicals
  • Innovacon（Alere, Abbott）

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 3 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
• Table 4 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 5 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market summary
• Fig. 4 Market segmentation & scope
• Fig. 5 Market size and growth prospects
• Fig. 6 U.S. point of care drug of abuse (DOA) testing market- Key market driver analysis
• Fig. 7 U.S. point of care drug of abuse (DOA) testing market - Key market restraint analysis
• Fig. 8 Penetration & growth prospect mapping
• Fig. 9 U.S. point of care drug of abuse (DOA) testing market - Porter's analysis
• Fig. 10 U.S. point of care drug of abuse (DOA) testing market - PESTEL analysis
• Fig. 11 U.S. point of care drug of abuse (DOA) testing market product outlook key takeaways
• Fig. 12 U.S. point of care drug of abuse (DOA) testing market: Product movement analysis
• Fig. 13 Immunoassay Test Strips and Cassettes
• Fig. 14 Oral Fluid Testing Kits market estimates, 2021 - 2033 (USD Million)
• Fig. 15 Breath Analyzers market estimates, 2021 - 2033 (USD Million)
• Fig. 16 Urine Collection Cups market estimates, 2021 - 2033 (USD Million)
• Fig. 17 Digital/Portable Analyzers market estimates, 2021 - 2033 (USD Million)
• Fig. 18 U.S. point of care drug of abuse (DOA) testing market sample type outlook key takeaways
• Fig. 19 U.S. point of care drug of abuse (DOA) testing market: sample type movement analysis
• Fig. 20 Urine market estimates, 2021 - 2033 (USD Million)
• Fig. 21 Saliva (Oral Fluid) market estimates, 2021 - 2033 (USD Million)
• Fig. 22 Breath market estimates, 2021 - 2033 (USD Million)
• Fig. 23 Blood market estimates, 2021 - 2033 (USD Million)
• Fig. 24 Sweat/Hair market estimates, 2021 - 2033 (USD Million)
• Fig. 25 U.S. point of care drug of abuse (DOA) testing market technology outlook key takeaways
• Fig. 26 U.S. point of care drug of abuse (DOA) testing market: technology movement analysis
• Fig. 27 Lateral Flow Assay (LFA) market estimates, 2021 - 2033 (USD Million)
• Fig. 28 Chromatographic Immunoassays market estimates, 2021 - 2033 (USD Million)
• Fig. 29 Enzyme-Linked Immunosorbent Assay (ELISA) market estimates, 2021 - 2033 (USD Million)
• Fig. 30 Mass Spectrometry (portable or hybrid POC units) market estimates, 2021 - 2033 (USD Million)
• Fig. 31 U.S. point of care drug of abuse (DOA) testing market end use outlook key takeaways
• Fig. 32 U.S. point of care drug of abuse (DOA) testing market: sample type movement analysis
• Fig. 33 Urine market estimates, 2021 - 2033 (USD Million)

U.S. Point Of Care DOA Testing Market Summary

The U.S. point of care drug of abuse (DOA) testing market size was estimated at USD 370.55 million in 2024 and is projected to grow at a CAGR of 9.3% from 2025 to 2033. The market is driven by an increasing need for rapid and on-site drug testing across multiple settings. Point-of-care DOA tests, which include urine, saliva, and occasionally blood-based panels, are widely used in workplaces, emergency departments, law enforcement, rehabilitation centers, and schools. These tests offer immediate results, helping healthcare professionals and institutions make faster decisions related to patient care, compliance, and risk mitigation. Their portability and ease of use are further increasing their adoption among non-laboratory professionals, contributing to market penetration.

One of the primary market drivers is the escalating incidence of drug abuse in the U.S., particularly related to opioids, cannabis, cocaine, and amphetamines. According to the National Center for Drug Abuse Statistics, over 20 million Americans aged 12 and older had a substance use disorder in 2023. This rising trend has heightened the demand for efficient drug screening tools, particularly in emergency and occupational health settings. Additionally, increased funding from federal agencies such as SAMHSA (Substance Abuse and Mental Health Services Administration) and state-level opioid response programs has bolstered the adoption of rapid testing tools.

Mandates for pre-employment, random, and post-incident drug testing in safety-sensitive industries such as transportation, construction, and healthcare are significantly contributing to market growth. The U.S. Department of Transportation (DOT) and other regulatory bodies have stringent requirements that compel employers to implement DOA screening protocols. POC testing is especially valued in these settings for its ability to quickly identify intoxication or recent drug use, helping mitigate legal liability and ensure workforce safety.

U.S. Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. point of care drug of abuse (DOA) testing market report based on product, sample type, technology, and end-use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay Test Strips and Cassettes
• Oral Fluid Testing Kits
• Breath Analyzers
• Urine Collection Cups
• Digital/Portable Analyzers
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Urine
• Saliva (Oral Fluid)
• Breath
• Blood
• Sweat/Hair
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Lateral Flow Assay (LFA)
• Chromatographic Immunoassays
• Enzyme-linked Immunosorbent Assay (ELISA)
• Mass Spectrometry (Portable or Hybrid POC Units)
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Emergency Departments
• Workplace & Occupational Health Center
• Home Care & Remote Users
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising substance abuse rates and opioid crisis
    • 3.3.1.2. Increased adoption in workplace and law enforcement
    • 3.3.1.3. Shift toward non-invasive and rapid testing methods
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Stringent Regulations
  • 3.3.3. Market Opportunities Analysis
  • 3.3.4. Market Challenges Analysis
    • 3.3.4.1. Product Recalls
• 3.4. U.S. Point of Care Drug of Abuse (DOA) Testing Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

• 4.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
• 4.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Product (USD Million), 2024 & 2033
• 4.3. Immunoassay Test Strips and Cassettes
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Oral Fluid Testing Kits
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Breath Analyzers
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Urine Collection Cups
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Digital/Portable Analyzers
  • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

• 5.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Movement Analysis
• 5.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Sample (USD Million), 2024 & 2033
• 5.3. Urine
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Saliva (Oral Fluid)
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Breath
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Blood
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Sweat/Hair
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

• 6.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
• 6.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Technology (USD Million), 2024 & 2033
• 6.3. Lateral Flow Assay (LFA)
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Chromatographic Immunoassays
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Mass Spectrometry (portable or hybrid POC units)
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

• 7.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End-use Movement Analysis
• 7.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by End-use (USD Million), 2024 & 2033
• 7.3. Hospitals & Emergency Departments
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Workplace & Occupational Health Center
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Home Care & Remote Users
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
• 8.5. Company Profiles/Listing
  • 8.5.1. Abbott
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Quest Diagnostics Inc
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Thermo Fisher Scientific
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. OraSure Technologies
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Siemens Healthineers
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. F. Hoffmann-La Roche Ltd.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Dragerwerk AG & Co. KGaA
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Premier Biotech
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. American Screening Corporation, Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Aegis Sciences Corporation
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. MP Biomedicals
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Innovacon (Alere, Abbott)
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives